Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 27, 2024, titled "Suven Life Sciences Announces FDA acceptance of Investigational New Drug (IND) and grant of Study may proceed Letter to initiate Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Receptor Positive Allosteric Modulator (M1-PAM)".